Exscientia up on deal to develop its AI-driven platform for blood cancer patients

Exscientia

07/03/2023 20:23

** U.S.-listed shares of British AI-driven pharma co
Exscientia PLC  EXAI.O  rise 5.6% to $6.95
    ** EXAI announces collaboration with one of the largest
university hospitals in Europe - Charité, to advance development
of its AI-driven functional drug testing platform to predict
patient response in blood related cancers
    ** Charité will expand on the results from EXAI's
prospective clinical trial that showed significantly improved
outcomes for late-stage blood cancer patients using its platform
    ** Charité will also establish a biobank that will contain
live human tissue samples for clinical and translational
research
    ** In 2022, U.S.-listed EXAI stock fell 73% 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))